Retatrutide, from Soma Corp., is attracting increasing attention as a potential treatment for obesity regulation. This unique read more medication merges the mechanism of a GLP-1 receptor agonist and a GIP receptor agonist , designed to simply promote reduced body fat but also target related metabolic factors. Initial human studies have shown encou